A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

ClinicalTrials.gov ID: NCT02836574

Public ClinicalTrials.gov record NCT02836574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).

Study identification

NCT ID: NCT02836574
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Prokidney; Industry
Enrollment: 83 participants

Conditions and interventions

Conditions

Interventions

Renal Autologous Cell Therapy (REACT) Biological
Renal Biopsy Procedure

Biological · Procedure

Eligibility (public fields only)

Age range: 30 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2016 (Actual)
Primary completion: Dec 2023 (Actual)
Completion: Dec 2023 (Actual)
Last update posted: Aug 24, 2025

2016 – 2023

United States locations

U.S. sites: 16
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Arizona	Tucson	Arizona	85724	—
Kidney Associates of Colorado	Denver	Colorado	80210	—
Yale Univeristy	New Haven	Connecticut	06520	—
University of Florida	Gainesville	Florida	32610	—
Boise Kidney and Hypertension Institute	Meridian	Idaho	83642	—
University of Chicago Medical Center	Chicago	Illinois	60637	—
University of Louisville	Louisville	Kentucky	40202	—
Renal Associates of Baton Rouge	Baton Rouge	Louisiana	70808	—
University of Michigan	Ann Arbor	Michigan	48109	—
Paragon Health	Kalamazoo	Michigan	49007	—
Nephrology & Hypertension Associates	Tupelo	Mississippi	38801	—
Mt. Sinai Hospital	New York	New York	45246	—
University of North Carolina- Chapel Hill	Chapel Hill	North Carolina	27599	—
Lehigh Valley Health Network	Allentown	Pennsylvania	18103	—
Vanderbilt University	Nashville	Tennessee	37212	—
University of Wisconsin-Madison	Madison	Wisconsin	53705	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02836574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2025 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02836574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →